Physician profile
Frederick O Lee
NPI 1063508679
$2,683.77
in general payments reported to CMS, 2019-2025
21 companies · $840 in 2025
The $840 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $190 · 2022: $286 · 2023: $421 · 2024: $946 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,207.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $690.85 | 2021-2025 | |
| Lilly USA, LLC | $330.73 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $304.51 | 2022-2025 | Freestyle Libre 3 |
| Alexion Pharmaceuticals, INC. | $230.78 | 2021-2022 | |
| Dexcom, INC. | $199.72 | 2024-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $188.82 | 2022-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.33 | 2023-2025 | Jardiance |
| Amgen INC. | $90.01 | 2024-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $79.83 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Ascendis Pharma Endocrinology INC | $75.58 | 2025 | Yorvipath |
| Xeris Pharmaceuticals, INC. | $60.89 | 2024-2025 | Gvoke Hypopen |
| Beta Bionics, INC. | $59.20 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Rhythm Pharmaceuticals, INC. | $27.05 | 2025 | Imcivree |
| Medtronic, INC. | $25.78 | 2024 | Minimed 780g |
| Ibsa Pharma INC. | $22.92 | 2025 | Flector, Tirosint, Licart |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $22.66 | 2025 | Omnipod |
| Horizon Therapeutics Plc | $22.15 | 2023 | Tepezza |
| Tandem Diabetes Care, INC. | $22.00 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $21.28 | 2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $20.95 | 2024 | |
| Madrigal Pharmaceuticals | $18.73 | 2025 | Rezdiffra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.